Laroprovstat

N/A

Report date: 2026/04/08 20:02:35
NME

Base Information

Drug NameLaroprovstat
Drug Alias NameAZD0780AZD-0780
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionProprotein convertase subtilisin kexin type 9 inhibitors
TargetsProprotein convertase subtilisin kexin type 9
Therapy Area/IndicationsHeterozygous familial hypercholesterolemiaDyslipidemiasAtherosclerosis +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBulgariaCanada +[41] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesDogma Therapeutics
China Registration ClassN/A

Develop Information

Active CompaniesAstraZeneca AB, R&D GothenburgAstrazeneca PlcAstrazeneca Ab +[4] 
Inactive CompaniesN/A
Active IndicationsHeterozygous familial hypercholesterolemiaDyslipidemiasAtherosclerosis +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A